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OBJECTIVE: To evaluate the effectiveness of nicotine replacement therapy (NRT), bupropion, nortriptyline and
combination therapy and describe factors associated with treatment success.
INTRODUCTION: Clinical trials clearly demonstrate the efficacy of pharmacotherapy in smoking cessation. However,
it is only after its use in real-life settings that clinical effectiveness and limitations of a treatment are fully known.
METHODS: Patients attended a four-session cognitive-behavioral program and received medicines free of charge.
Abstinence from smoking was assessed at each visit.
RESULTS: A total of 868 smokers (68.8% women) were included. Their mean age was 49.6 years; the amount smoked
was 25 cigarettes/day and the Fagerstro¨m Score was 6.6. Abstinence rates after 6 months and 1 year were 36.5% and
33.6%. In univariate analysis, male gender, age (.50), higher number of cigarettes smoked, cardiovascular
comorbidities, longer interval from the last cigarette and combined treatment of nortriptyline plus NRT were
predictive of abstinence, while neuropsychiatric comorbidities and the answer ‘‘yes’’ to the question ‘‘Do you smoke
more often during the first hours after waking’’ were correlated with failure. In a multivariate model, predictors of
abstinence were neuropsychiatric comorbidities, the answer ‘‘yes’’ to the question ‘‘Do you smoke more often
during the first hours after waking’’ and combined treatment of nortriptyline plus NRT. Male gender and a longer
period from the last cigarette were correlated with lower abstinence rate.
CONCLUSION: Satisfactory success rates were obtained in a teaching hospital. Factors such as age, daily cigarette
consumption, number of pack-years and dependency score were not reliable markers of abstinence. The
combination nortriptyline+NRT was independently associated with higher abstinence rates.
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INTRODUCTION
Cigarette smoking remains one of the primary healthcare
concerns world wide and continues to be the major cause of
morbidity and mortality in the world. Five million people
die yearly world wide owing to tobacco-related diseases. If
current trends continue, tobacco will kill 1000 million
people prematurely during this century.1 Several studies
have reported that 60–70% of smokers want to quit2 and
intend to stop, but only 3–5% of them remain abstinent for a
year after an unassisted attempt.3 ‘‘Offer help to quit
tobacco use’’ in people addicted to nicotine is one of the
six proven policies identified by WHO to expand the fight
against the tobacco epidemic.
Pharmacological treatment is an important resource in
smoking cessation. Several randomized, double-blind, pla-
cebo-controlled trials have reported significantly higher
abstinence rates with first-line, and some second-line, drugs
compared with placebo. These clinical trials provide
scientific evidence of the efficacy and safety of nicotine
replacement therapy (NRT),4 bupropion (BUP),5,6 vareni-
cline7,8 and nortriptyline (NOR),9 a dopaminergic tricyclic
antidepressant used as second-line smoking cessation
therapy; however, the effectiveness and limitations of these
drug regimens in real-life settings are still poorly docu-
mented.
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Most randomized controlled trials have exclusion criteria,
generally prohibiting entrance to the trial of patients with
comorbidities and those with multiple or recent attempts to
quit.10 Those patients, especially those with cardiovascular
and psychiatric disorders, frequently attend tertiary smok-
ing cessation clinics such as ours.
The aim of this retrospective study was to assess the
effectiveness of NRT, BUP, NOR and some combined
schemes plus cognitive-behavioral intervention when used
under clinical practice conditions and to investigate the role
of different demographic and individual factors as pre-
dictors of abstinence.
MATERIALS AND METHODS
A retrospective interventional study was carried out
among smokers motivated to quit attending the pulmonary
division of Hospital das Clinicas, University of Sa˜o Paulo
Medical School (Sa˜o Paulo, SP, Brazil) Smoking Cessation
Clinic from 2003 to 2008. These smokers were included in
the study, independently of the number of cigarettes
smoked a day, number of pack-years or number of previous
attempts to quit. All patients freely signed an informed
consent form. Exclusion criteria were pregnancy and
impossibility of attending the four sessions of the cogni-
tive-behavioral program. Consultations were always held in
the afternoons.
All smokers received a standardized program for smok-
ing cessation including pharmacological and cognitive-
behavioral interventions, consisting of four 60-minute
structured group sessions (dealing with aspects of smok-
ing-related morbidity and mortality, key issues of nicotine
addiction and the development of a specific action plan for
stopping smoking) during the pretreatment period.
Pharmacotherapy consisted of NRT, NOR, BUP and NRT
combined with NOR or BUP and was assigned depending
on availability (supplied by the public health system, free of
charge) and physician’s discretion. Treatment always began
2 weeks before the target quit day for BUP and NOR users
and on the day before quitting for patients receiving NRT.
Pharmacological therapy was prescribed for at least 12
weeks.
Patients attended follow-up control visits at weeks 2, 4, 8
and 12 after the scheduled quit day and monthly until the
sixth month. Abstinence at 1 year was assessed, when
possible, by telephone call.
Patients who missed their appointments or did not
answer the phone calls were considered smokers (inten-
tion-to-treat analysis).
At baseline a detailed smoking history and health data,
using a three-domain structured anamnesis, were gathered.
Questionnaires included questions on gender, age, cigarette
initiation, number of cigarettes per day and Fagerstro¨m test
for nicotine dependence (FTND), time from last cigarette,
previous attempts to quit, presence of other smokers in the
household and former and current diseases and medica-
tions. Self-reported cigarette consumption, exhaled CO level
(COex), weight and possible adverse effects were measured
at all follow-up visits. Effectiveness was measured as 7-day
point prevalence abstinence rate confirmed by COex levels
of #9 ppm from week 2 through the sixth month.
Psychiatric comorbidity was assessed using the Diag-
nostic and Statistical Manual of Mental Disorders,11 fourth
edition (DSM-IV) and self-reported diagnostics. Weight was
recorded at every appointment. Data were first entered into
a relational database (Microsoft Excel, Microsoft Corp,
Redmond, Washington, USA) and then converted into an
SAS file (SAS 9.0, SAS Institute Inc, North Carolina, USA). In
the descriptive analysis, categorical variables are expressed
as proportions, and continuous variables as mean (with
standard deviation) and median, when they have no normal
distribution.
Univariate (crude) analysis of variables from the entire
population was performed using a x2 test and two-sample
test for continuous data. Data were expressed as an odds
ratio and 95% confidence interval. All tests used a
significant level of 0.05.
Multivariate logistic regression was used to identify
independent predictors (adjusted odds ratio and 95%
confidence interval) associated with abstinence. Models
were fitted, including all factors associated with the
outcome, in a stepwise procedure. Factors were subse-
quently eliminated from the model if the x2 statistic of
likelihood ratio test indicated no statistical significance.
RESULTS
Of a total of 1112 patients who attended the first
appointment and began the treatment, 244 (21.9%) refused
to participate in the structured program and did not attend
the following meetings for group therapy.
Of the 868 patients who were assisted by the program, 597
were women (68.8%) and 271 men (31.2%), with a mean age
of 49.6 years (range 21–82), who smoked an average of 25
cigarettes per day and 39.7 pack-years.
Baseline information and demographic characteristics of
the participants are reported in Table 1.
The mean age of initiation was 15 years (SD 5.7); the
distribution of subjects according to age of initiation is
shown in Figure 1.
The results of the FTND (Figure 2) showed a sample of
individuals with a moderate-to-high degree of dependence
(mean score 6; median 7; SD 2).
About 81.8% of patients had made at least one previous
attempt to stop smoking.
Of the women who had at least one pregnancy (n= 379),
272 (71.8%) smoked during gestation.
Table 1 - Demographic data and descriptive analysis
Characteristics Value
Number 868
Gender, M/F (%) 31.2/68.8
Age (years) 49.6¡10.7
Educational status (years) 8.5¡5.3
Weight (kg) 67¡15
FTND Score* 6¡2 (0–10)
COex (ppm) 22¡12
Age of initiation (years)* 15¡5.7 (3–62)
Number of cigarettes/day 25¡20
Pack-years 39.7¡21.7
Respiratory comorbidities (%) 25
Cardiovascular comorbidities (%) 34
Neuropsychiatric comorbidities (%) 51
Time from last cigarette at first appointment (min) 120¡232 (2–1440)
*Expressed in mean¡SD (range).
COex = exhaled CO; FTND = Fagerstro¨m test for nicotine dependence;
SD = standard deviation.
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More than a third of subjects had an associated disease
(25% respiratory, 34% cardiovascular and 51% psychiatric
comorbidity). Of those subjects, 82.5% had made at least one
previous attempt to quit smoking and 41.8% had another
smoker (or smokers) at home.
The distribution of treatment options was as follows: 74%
NRT (n= 642), 8% NOR (n= 69), 8% NOR plus NRT (n= 70),
6% BUP plus NRT (n= 52) and 4% BUP alone (n = 35).
Success rates at 4 weeks, 8 weeks, 16 weeks, 6 months and
1 year are summarized in Figure 3.
For the variable ‘‘time from last cigarette at first
appointment’’, values above and below the cut-off point at
the median (120 min) were chosen in order to make this
variable categorical. Intervals were also described as
quartiles to study trends.
In the logistic procedure for multivariate analysis, there
were no statistically significant differences in 7-day point
prevalence at 1 year for age, gender, COex, FTND Score,
pack-years, comorbidities (cardiovascular, mental and
respiratory) and type of drug therapy used. Only the time
from last cigarette at first appointment .120 min (OR=1.17;
95% CI 1.07–1.28, p,0.0001) was a predictor of success.
There was a linear relationship between the time from the
last cigarette (separated into quartiles) at first visit and
abstinence rate after 1 year (Cochran–Armitage Trend Test,
p = 0.0038). The greater the time, the greater the success rate
(Figure 4)
Having analyzed the success rates according to the
combination of drugs used, we obtained the results shown
in Figure 5. The combination of NOR+NRT was the most
effective option (46.4% in 1 year). There was a statistically
significant difference between the result of this combination
and other treatment options (OR = 1.6; 95% CI 1.1–2.4,
p,0.05). There was no statistically significant difference
among the other treatment options.
Weight gain was an important concern in our study
(Table 2), affecting 79.5% and 57.4% of patients, after
6 months and 1 year, respectively. From those who showed
a weight increase, the mean gain was 7.5% (SD 6.1%) or
4.9 kg, at 6 months and 6.8% (SD 8%) or 5 kg, after 1 year. A
Figure 1 - Age of initiation (years).
Figure 2 - Distribution of Fagerstro¨m test for nicotine dependence (FTND) Scores.
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comparison of people who had stopped smoking with those
who continued to smoke showed a statistically significant
difference in both period.
In univariate analysis (Table 3), gender (male), age
(.50 years), cigarettes smoked (above the median of 35
pack-years), the presence of cardiovascular comorbidities,
the interval from the last cigarette smoked before the first
consultation (fourth quartile versus others) and the com-
bined treatment of NOR+NRT were predictive of abstinence
after 1 year, while the existence of neuropsychiatric
comorbidities and the answer ‘‘yes’’ to the question ‘‘Do
you smoke more often during the first hours after waking
than during the rest of the day?’’ of Fagerstro¨m’s
Questionnaire were predictive of failure.
In the multivariate model, however, only five of these
factors were correlated with the outcome. The presence of
neuropsychiatric comorbidities, the answer ‘‘yes’’ to the
question ‘‘Do you smoke more often during the first hours
after waking than during the rest of the day?’’ and the
combined treatment of NOR+NRT predicted higher odds of
abstinence at 1 year. Male gender and longer period from
last cigarette at the first attendance were correlated with
lower odds of abstinence at 1 year.
DISCUSSION
This retrospective study shows data on tobacco absti-
nence after a period of clinical treatment for smoking
cessation with real-life pharmacological schemes and
cognitive-behavioral intervention and, also, analyzes mar-
kers of success in an off-trial clinical context.
The effectiveness data presented in this study are
slightly better than those reported in the original clinical
trials.12 The corresponding real-setting abstinence rates at
Figure 3 - Seven-day point prevalence abstinence rates at 4 weeks, 8 weeks, 16 weeks, 6 months and 1 year, according to gender.
Figure 4 - Success rates at 1 year, according to time from last cigarette at first appointment, displayed in quartiles.
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52 weeks ranged from 38.1% for men to 31.6% for women,
with no statistically significant difference between the two
groups.
Identification of individual characteristics that predict
success in smoking cessation is highly desirable, but not
always feasible. A number of common predictors have been
described as personal, social and psychological factors. In
our population, however, age of initiation, educational
status, dependency score (FTND), cigarette consumption,
exhaled carbon monoxide level and the existence of
respiratory comorbidities did not predict smoking cessation.
We observed data on gender differences that are similar
to those found in previously published reports. There is
evidence that women are more likely to seek assistance in
their attempts to quit than are men3, but there is some
controversy about whether women benefit from specific
pharmacological interventions (NRT, for instance) as much
as men.13,14
Our study clearly demonstrates an early initiation into
smoking, with over 68% of patients having started smoking
before the age of 18 years. The median smoking initiation
age in our group was similar to that described by Menezes
and colleagues,15 both for the city of Sa˜o Paulo (16.2 and 18.3
years for boys and girls, respectively) and for the average of
other Latin American cities studied (18.2 years).
Weight gain in our population was also similar to that in
other studies, such as that reported by Klesges et al.,16
which demonstrated a mean increase of 5 kg in abstinent
patients after 1 year. In contrast to data published by
Williamson and colleagues,17 weight gain, which is strongly
related to smoking cessation, occurred in the majority of
those who stopped smoking. Some potential cosmetic effects
of weight gain may negatively interfere with attempts to
quit and thus, should be considered as an important
problem in a cognitive-behavioral approach and counseling,
especially for women.
In our center, with highly motivated patients, many of
them with comorbidities, a high Fagerstro¨m Score was not a
predictor of lower abstinence rates. Another intriguing
finding was that smoking more in the early hours of the day
was not confirmed in multivariate analysis as a factor
related to treatment failure. Perhaps the restrictions on
smoking indoors (which can directly influence the number
of cigarettes smoked during the day and times at which one
smokes more—possibly after the work shift) may explain
these findings and signal the eventual need for future
Figure 5 - Seven-day point prevalence abstinence rates according to drug options. BUP = bupropion; NOR = nortriptyline; NRT =
nicotine replacement therapy.
Table 2 - Weight gain in 6 months and 1 year, according to subgroup analysis.
6 Months 1 Year
Absolute gain (kg¡SD) Percentage gain (%¡SD) Absolute gain (kg¡SD) Percentage gain (%¡SD)
General 4.3¡4.6 5.8¡7.1 1.5¡7.5 2.2¡10
Abstinent* 4.2¡4.3 6.8¡6.7 5.0¡7.0 7.1¡9.8
Present smokers 5.1¡2.4 3.7¡7.7 -0.4¡5.7 -0.4¡6.7
*p,0.05 compared with present smokers in 6 months and 1 year.
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reviews of the questionnaire and its descriptors in light of
recent changes in the pattern of cigarette consumption.
In univariate analysis, the variable defined as the time
elapsed since the last cigarette and the first visit proved to
be a predictor of success, which encourages the hypothesis
that this factor could be recognized as an indicator of
dependence (ie, the shorter the time, the higher the degree
of dependence). However, this hypothesis was not con-
firmed in the multivariate model, indicating the need for
confirmation in prospective studies.
A particular aspect of our study is the use of NOR, a
tricyclic antidepressant with some evidence of efficacy in
smoking cessation in small studies,18,19,20 but classified in
guidelines as a second-line drug owing to its side effects
profile and conflicting results in larger controlled trials.21
From our point of view, and in agreement with the findings
from the meta-analysis of Wagena and colleagues,22 it is a
significant treatment option, given its efficacy (comparable
to those first-line options), safety and, especially, its low cost
and wide availability. Perhaps, considering the threat of a
global tobacco epidemic—and even more significant
impacts on the less affluent nations—the inclusion of NOR
in the therapeutic arsenal of smoking cessation may be a
promising step towards a wider access to treatment,
especially in developing countries.
Based on our findings, we propose the inclusion of NOR
among the list of first-line drugs for smoking cessation.
The major limitation of this report is that it was
retrospective, uncontrolled and not randomized. The avail-
able options of treatment regimens were chosen by
individual criteria on a case-by-case basis or according to
the availability of medicines in the public health system.
Another significant limitation of our study was that the
sample size allocated to each treatment group was very
different, which may have compromised, to some extent, the
validity of the comparison between them and, eventually,
the reliability of these data.
Nevertheless, the proof of results previously demon-
strated in randomized controlled clinical trials shows that
treatment of smoking cessation in clinical practice is feasible
and effective.
CONCLUSIONS
Despite the broad therapeutic armamentarium available,
smoking cessation is still a therapeutic challenge all around
the world. The different individual or combined pharma-
cotherapy regimens provide modest success rates—around
30–35% in 1 year. Another potential difficulty is translating
the results observed in clinical trials into daily clinical
practice, which in part can be explained by the fact that
‘‘real’’ patients do not always resemble those subjects
participating in randomized controlled studies.
In a teaching hospital with students in training, our group
has achieved satisfactory success rates, treating patients
with high levels of dependence and high prevalence of
comorbidities. Combining NRT with NOR yielded more
favorable results.
Factors such as gender, age, number of pack-years,
dependency score were not good predictors of success or
markers of lower abstinence rates in smoking cessation
treatment in this particular group of patients.
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